Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Arteriosclerosis Obliterans D001162 8 associated lipids
Encephalitis D004660 15 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Contracture D003286 3 associated lipids
Stomatitis D013280 14 associated lipids
Weight Loss D015431 56 associated lipids
Endotoxemia D019446 27 associated lipids
Blister D001768 16 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Lupus Nephritis D008181 8 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Ileal Diseases D007077 3 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Gliosis D005911 6 associated lipids
Neuralgia D009437 28 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Amnesia D000647 12 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Sneezing D012912 6 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Liver Failure D017093 5 associated lipids
Hepatitis, Alcoholic D006519 5 associated lipids
Helicobacter Infections D016481 21 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Mucositis D052016 7 associated lipids
Ileitis D007079 2 associated lipids
Carcinoma, Embryonal D018236 8 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Neoplastic Cells, Circulating D009360 5 associated lipids
Corneal Neovascularization D016510 8 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Shock, Cardiogenic D012770 5 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Strongylida Infections D017206 5 associated lipids
Enterocolitis, Necrotizing D020345 3 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Venous Thrombosis D020246 11 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Mouth, Edentulous D009066 1 associated lipids
Pelvic Pain D017699 7 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Capillary Leak Syndrome D019559 2 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Migraine without Aura D020326 1 associated lipids
Peanut Hypersensitivity D021183 2 associated lipids
Egg Hypersensitivity D021181 1 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Pneumonia, Pneumococcal D011018 3 associated lipids
Dictyocaulus Infections D004022 1 associated lipids
Bovine Virus Diarrhea-Mucosal Disease D001912 2 associated lipids
Jaundice, Obstructive D041781 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Leukostasis D018921 1 associated lipids
Pulmonary Atelectasis D001261 1 associated lipids
Viremia D014766 4 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Brain Hemorrhage, Traumatic D020201 1 associated lipids
Bronchiectasis D001987 7 associated lipids
Anthrax D000881 1 associated lipids
Heart Injuries D006335 6 associated lipids
Arenaviridae Infections D001117 1 associated lipids
Neurologic Manifestations D009461 1 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Hirt SW et al. Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. 1992 Transpl. Int. pmid:14621825
Torras J et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. 1993 Transpl. Int. pmid:8347271
Räisänen A et al. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. 1993 Transpl. Int. pmid:8216700
Wang KS et al. Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. 1992 Transplant. Proc. pmid:1496669
Takada Y et al. Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. 2000 Transplant. Proc. pmid:10715416
Fukuoka T et al. Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion. 1993 Transplant. Proc. pmid:8470175
Peyman JA et al. HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. 1992 Transplant. Proc. pmid:1533073
Taniguchi S et al. Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. 1994 Transplant. Proc. pmid:8171719
Coughlan AF et al. In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. 1993 Transplant. Proc. pmid:7692651
Hammer C et al. Xenogeneic rejection mechanisms shown by intravital microscopy. 1998 Transplant. Proc. pmid:9865335
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Fukunaga K et al. Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. 1998 Transplant. Proc. pmid:9838664
Lloberas N et al. The ether phospholipids trail: blood timing in renal ischemia-reperfusion injury. 2002 Transplant. Proc. pmid:11959179
Castellvi J et al. Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. 2002 Transplant. Proc. pmid:11959181
Metcalfe SM et al. Survival of renal allografted dogs after limited therapy with cyclosporine and the PAF antagonist WEB 2170. 1991 Transplant. Proc. pmid:1871852
Pirotzky E et al. Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. 1988 Transplant. Proc. pmid:3388505
Keskinoglu A et al. Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9122948
Otte KE et al. Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. 1990 Transplant. Proc. pmid:2349668
Moreno P et al. Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. 1993 Transplant. Proc. pmid:8395105
Kecskemeti V and Balogh I Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. 1995 Transplant. Proc. pmid:7482928
Yin M et al. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7482939
Spiegel HU et al. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. 1995 Transplant. Proc. pmid:7482955
Foegh ML Eicosanoids and platelet activating factor mechanisms in organ rejection. 1988 Transplant. Proc. pmid:3059615
Mahmoud FF et al. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. 2002 Transplant. Proc. pmid:12431672
Borobia FG et al. Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. 1993 Transplant. Proc. pmid:8356661
Toledo-Pereyra LH and Suzuki S Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. 1994 Transplant. Proc. pmid:8109001
Iwamoto H et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. 2000 Transplant. Proc. pmid:11119873
Da Costa M et al. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. 1990 Transplant. Proc. pmid:2389490
Bergmann R et al. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. 1990 Transplant. Proc. pmid:2389511
Immunomodulation: other approaches. 1988 Transplant. Proc. pmid:3347955
Renkonen R et al. Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. 1991 Transplant. Proc. pmid:1846709
O'Hair DP et al. Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. 1992 Transplant. Proc. pmid:1566490
Pignol B et al. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. 1988 Transplant. Proc. pmid:3259039
Miyatake T et al. Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. 2000 Transplant. Proc. pmid:10936319
First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. 1986 Transplant. Proc. pmid:3765055
Minor T et al. Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. 1995 Transplant. Proc. pmid:7879086
Ide S et al. Donor administration of PAF antagonist (TCV-309) enhances lung preservation. 1995 Transplant. Proc. pmid:7879103
Takada Y et al. Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. 1995 Transplant. Proc. pmid:7879169
Yin M et al. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7879180
Pi F et al. Effect of a platelet-activating factor antagonist and desferrioxamine administration on eicosanoid production in rat pancreas transplantation. 1994 Transplantation pmid:8291097
Lanese DM et al. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. 1994 Transplantation pmid:7809931
dos Santos OF et al. Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation. 1989 Transplantation pmid:2705209
Makowka L et al. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts. 1990 Transplantation pmid:2402783
Biancone L et al. Platelet-activating factor synthesis and response on pancreatic islet endothelial cells: relevance for islet transplantation. 2006 Transplantation pmid:16495796
Gu M et al. Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors. 2000 Transplantation pmid:11045637
Saumweber DM et al. Hyperacute rejection in an ex vivo model of renal xenografting. Role of the mediator response and its pharmacologic manipulation by the specific platelet-activating factor antagonist WEB 2086BS. 1994 Transplantation pmid:8108870
Biancone L et al. Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells. 2000 Transplantation pmid:11063341
Yin M et al. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. 1996 Transplantation pmid:8633367
Watson CJ et al. The platelet-activating factor antagonist WEB 2170. Its beneficial effect on dog renal allograft survival. 1993 Transplantation pmid:8212192
Suzuki S et al. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. 2000 Transplantation pmid:10868624